The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. 19 weeks [clinicaltrials_resource:889c69001719f1b3a8a921516f117225]
900 mg once a day for 8 weeks
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. 19 weeks [clinicaltrials_resource:889c69001719f1b3a8a921516f117225]
900 mg once a day for 8 weeks
Bio2RDF identifier
889c69001719f1b3a8a921516f117225
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:889c69001719f1b3a8a921516f117225
measure [clinicaltrials_vocabulary:measure]
The reduction in percent days ...... on versus off valganciclovir.
time frame [clinicaltrials_vocabulary:time-frame]
description
900 mg once a day for 8 weeks
identifier
clinicaltrials_resource:889c69001719f1b3a8a921516f117225
title
The reduction in percent days ...... s off valganciclovir. 19 weeks
@en
type
label
The reduction in percent days ...... c69001719f1b3a8a921516f117225]
@en